Bharat Biotech phase 3 ends today, no side effects reported, 99.6% efficacy reported in phase 2. We should get phase 3 efficacy next week which is what will send this if numbers still great. Company already in talks with FDa and manufacturers, so once results come they should be allowed to use some of the data from India trials.
Brazil and India already granted EAU for this vaccine, which is promising.
News 
Market Data 
Discover 
